Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 20/100

ADMA FRAUD ALERT: BFA Law is Investigating ADMA Biologics, Inc. for Securities Fraud after Stock Drops 20%; Investors with Losses are Urged to Contact the Firm (Nasdaq:ADMA)

Key Takeaway: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics, Inc. for potential securities fraud after a significant 20% drop in the company's stock price. This decline followed the unexpected resignation of the company's independent auditor, CohnReznick LLP, on October 9, 2024. Investors are encouraged to reach out for more information, as the firm suggests legal options may be available for those affected by the stock decline.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics' stock dropped over 20% following the resignation of its independent auditor.
  • The investigation into ADMA Biologics raises concerns about potential violations of federal securities laws.
  • The adverse financial impact may affect investor confidence and the company's future.

Full Press Release Details

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Why Did ADMA Biologics’s Stock Drop?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
If you invested in ADMA Biologics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.

Tags

Frequently Asked Questions

What prompted the investigation into ADMA Biologics?

Bleichmar Fonti & Auld LLP is investigating ADMA Biologics for potential securities law violations.

Why did ADMA Biologics's stock drop recently?

The sudden resignation of ADMA's independent auditor led to a more than 20% stock decline.

What does ADMA Biologics do?

ADMA Biologics manufactures and develops specialty biologics for immunodeficient patients.

How can investors get more information?

Investors can visit BFA's website for information regarding ADMA Biologics.

What are the legal options for ADMA investors?

Investors may have legal options and can submit their information to BFA for assistance.

Last updated: Oct 11, 2024